Short-Selling Reform Is On BIO Wish List For Stimulus Bill
This article was originally published in The Pink Sheet Daily
Executive Summary
Small public biotechs are especially vulnerable to market manipulation, association notes.
You may also be interested in...
BIO Says Tax Revisions Would Relax Tight Money For Biotechs
Tax measures that provide cash and encourage investment in the biotech sector should be part of economic stimulus package, group says.
Pozen/AZ Combo Pill Could See Setback As FDA Reviews Trial Endpoints
Phase III studies of the NSAID/PPI combination are set to wrap up, but agency now is reviewing use of endoscopic gastric ulcers as an endpoint.
GSK/Pozen Win Long-awaited Approval For Combo Migraine Drug
Treximet will hit the U.S. market in mid-May, GSK says.